IL166121A0 - Indole-3-sulphur derivatives - Google Patents

Indole-3-sulphur derivatives

Info

Publication number
IL166121A0
IL166121A0 IL16612105A IL16612105A IL166121A0 IL 166121 A0 IL166121 A0 IL 166121A0 IL 16612105 A IL16612105 A IL 16612105A IL 16612105 A IL16612105 A IL 16612105A IL 166121 A0 IL166121 A0 IL 166121A0
Authority
IL
Israel
Prior art keywords
indole
sulphur derivatives
sulphur
derivatives
Prior art date
Application number
IL16612105A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL166121A0 publication Critical patent/IL166121A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
IL16612105A 2002-07-17 2005-01-03 Indole-3-sulphur derivatives IL166121A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202241A SE0202241D0 (sv) 2002-07-17 2002-07-17 Novel Compounds
SE0203713A SE0203713D0 (sv) 2002-07-17 2002-12-13 Novel compounds
PCT/SE2003/001216 WO2004007451A1 (en) 2002-07-17 2003-07-15 Indole-3-sulphur derivatives

Publications (1)

Publication Number Publication Date
IL166121A0 true IL166121A0 (en) 2006-01-15

Family

ID=30117585

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16612105A IL166121A0 (en) 2002-07-17 2005-01-03 Indole-3-sulphur derivatives

Country Status (23)

Country Link
US (2) US7723373B2 (pt)
EP (1) EP1551802B1 (pt)
JP (3) JP4791729B2 (pt)
CN (1) CN1279023C (pt)
AR (1) AR040498A1 (pt)
AT (1) ATE450506T1 (pt)
AU (1) AU2003251260B2 (pt)
BR (1) BR0312729A (pt)
CA (1) CA2492445A1 (pt)
CY (1) CY1109760T1 (pt)
DE (1) DE60330372D1 (pt)
DK (1) DK1551802T3 (pt)
ES (1) ES2335491T3 (pt)
IL (1) IL166121A0 (pt)
MX (1) MXPA05000646A (pt)
NO (1) NO20050828L (pt)
NZ (1) NZ537606A (pt)
PT (1) PT1551802E (pt)
SE (2) SE0202241D0 (pt)
SI (1) SI1551802T1 (pt)
TW (1) TW200404778A (pt)
WO (1) WO2004007451A1 (pt)
ZA (1) ZA200500170B (pt)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
DK1648867T3 (da) * 2003-07-17 2013-12-16 Plexxikon Inc Ppar-aktive forbindelser
US7348338B2 (en) 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
BRPI0415437A (pt) * 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
KR100808742B1 (ko) 2004-03-11 2008-02-29 액테리온 파마슈티칼 리미티드 테트라하이드로피리도인돌 유도체
GB0412914D0 (en) * 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) * 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
JP5063348B2 (ja) * 2004-08-26 2012-10-31 アクテリオン ファーマシューティカルズ リミテッド ２−スルファニル−ベンゾイミダゾール−１−イル−酢酸誘導体
JP2008513512A (ja) 2004-09-21 2008-05-01 アサーシス， インク． Ｃｒｔｈ２受容体拮抗作用を示すインドール酢酸およびこれらの使用
US7183309B2 (en) * 2004-10-27 2007-02-27 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
WO2006056752A1 (en) 2004-11-23 2006-06-01 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
JP2008521829A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US20060135540A1 (en) * 2004-11-30 2006-06-22 Jack Lin PPAR active compounds
DK1833791T3 (da) 2004-12-27 2011-10-24 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
WO2006090817A1 (ja) * 2005-02-25 2006-08-31 Ono Pharmaceutical Co., Ltd. インドール化合物およびその用途
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
WO2007010964A1 (ja) 2005-07-22 2007-01-25 Shionogi & Co., Ltd. Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
TW200800872A (en) * 2005-09-07 2008-01-01 Plexxikon Inc PPAR active compounds
US20080234349A1 (en) * 2005-09-07 2008-09-25 Jack Lin PPAR active compounds
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
GB0525143D0 (en) * 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0526257D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
CN101454284A (zh) 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
WO2007149312A2 (en) 2006-06-16 2007-12-27 The Trustees Of The University Of Pennsylvania Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and bph
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
SI2051962T1 (sl) 2006-08-07 2012-02-29 Actelion Pharmaceuticals Ltd Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
GB0722055D0 (en) * 2007-11-09 2007-12-19 Argenta Discovery Ltd Compounds
CN101970405A (zh) 2007-12-14 2011-02-09 普尔马金医疗(哮喘)有限公司 吲哚及其治疗用途
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
ES2442717T3 (es) * 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093029A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
CN102482214B (zh) 2009-07-06 2014-08-27 阿斯利康(瑞典)有限公司 制备4-(乙酰基氨基)-3-[(4-氯-苯基)硫基]-2-甲基-1h-吲哚-1-乙酸的中间体和方法
WO2011055270A1 (en) 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
EA201200855A1 (ru) 2009-12-23 2013-04-30 Айронвуд Фармасьютикелз, Инк. Модуляторы crth2
WO2011115804A1 (en) 2010-03-17 2011-09-22 Ironwood Pharmaceuticals, Inc. Sgc stimulators
DK2558447T3 (da) 2010-03-22 2014-11-10 Actelion Pharmaceuticals Ltd 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazolderivater og deres anvendelse som prostaglandin d2-receptormodulatorer
US8598223B2 (en) 2010-06-21 2013-12-03 Ono Pharmaceutical Co., Ltd. Crystalline forms of 4, 4′-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4′-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4′-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid
EP3173407A1 (en) 2010-06-30 2017-05-31 Ironwood Pharmaceuticals, Inc. Sgc stimulators
US20130216552A1 (en) 2010-07-12 2013-08-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
WO2012009134A1 (en) 2010-07-12 2012-01-19 Ironwood Pharmaceuticals, Inc. Crth2 modulators
RU2016101964A (ru) 2010-11-09 2018-11-21 Айронвуд Фармасьютикалз, Инк. СТИМУЛЯТОРЫ sGC
MY165623A (en) 2011-04-14 2018-04-18 Idorsia Pharmaceuticals Ltd 7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP6054600B2 (ja) * 2011-08-11 2016-12-27 富士通コンポーネント株式会社 コネクタ
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
US9139564B2 (en) 2011-12-27 2015-09-22 Ironwood Pharmaceuticals, Inc. 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators
CN104602763B (zh) 2012-03-21 2018-08-21 宾夕法尼亚大学理事会 用于调节毛发生长的组合物和方法
WO2014047111A1 (en) 2012-09-18 2014-03-27 Ironwood Pharmaceuticals, Inc. Sgc stimulators
EP2897953B8 (en) 2012-09-19 2019-06-26 Cyclerion Therapeutics, Inc. Sgc stimulators
BR112015023349A2 (pt) 2013-03-15 2017-07-18 Ironwood Pharmaceuticals Inc composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
MX2016007522A (es) 2013-12-11 2017-12-15 Ironwood Pharmaceuticals Inc Estimuladores de guanilato ciclasa soluble (sgc).
WO2015106268A1 (en) 2014-01-13 2015-07-16 Ironwood Pharmaceuticals, Inc. USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS
LT3119779T (lt) 2014-03-17 2018-09-10 Idorsia Pharmaceuticals Ltd Azaindolo acto rūgšties dariniai ir jų panaudojimas kaip prostaglandino d2 receptoriaus moduliatorių
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
JP2017527604A (ja) 2014-09-17 2017-09-21 アイアンウッド ファーマシューティカルズ インコーポレイテッド ｓＧＣ刺激剤
US20170298055A1 (en) 2014-09-17 2017-10-19 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
WO2016044447A1 (en) 2014-09-17 2016-03-24 Ironwood Pharmaceuticals, Inc. Pyrazole derivatives as sgc stimulators
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
KR20180031019A (ko) 2015-07-30 2018-03-27 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Ｐｇｄ２에 의한 모발 성장 억제에 대한 민감성의 검출을 위한 인간 ｄｐ―２ 유전자의 단일 뉴클레오티드 다형성 대립유전자
CA2993893A1 (en) 2015-09-15 2017-03-23 Idorsia Pharmaceuticals Ltd Crystalline forms
BR112019000290B1 (pt) 2016-07-07 2022-10-18 Cyclerion Therapeutics, Inc Prófármacos de fósforo dos estimuladores da sgc
KR20190025989A (ko) 2016-07-07 2019-03-12 아이언우드 파마슈티컬스, 인코포레이티드 sGC 자극제의 고체 형태
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US741360A (en) * 1899-11-13 1903-10-13 William M Moseley Toy.
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
IL84796A (en) * 1986-12-17 1992-03-29 Merck Frosst Canada Inc Substituted n-benzyl-indoles and pharmaceutical compositions containing them
US5095031A (en) * 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
CA2079374C (en) * 1991-09-30 2003-08-05 Merck Frosst Canada Incorporated (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
CA2156420A1 (en) 1993-02-24 1994-09-01 Theresa M. Williams Inhibitors of hiv reverse transcriptase
US5486525A (en) * 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5482960A (en) * 1994-11-14 1996-01-09 Warner-Lambert Company Nonpeptide endothelin antagonists
US5567711A (en) * 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
TW472045B (en) * 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ZA987554B (en) 1997-08-21 2000-02-21 American Home Prod Methods for the solid phase synthesis of substituted indole compounds.
ES2198033T3 (es) 1997-12-19 2004-01-16 Eli Lilly And Company Compuestos de imidazolina hipoglucemicos.
US6916841B2 (en) * 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
AU5886500A (en) 1999-06-23 2001-01-09 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
CN1615873A (zh) 1999-12-24 2005-05-18 阿文蒂斯药物有限公司 氮杂吲哚类化合物
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
CA2461670A1 (en) * 2001-09-27 2003-04-10 F. Hoffmann-La Roche Ag Indole derivatives as cox ii inhibitors
US6933316B2 (en) * 2001-12-13 2005-08-23 National Health Research Institutes Indole compounds
ATE340792T1 (de) 2002-02-01 2006-10-15 Hoffmann La Roche Substituierte indole als alpha-1 agonisten
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP2423190A1 (en) 2002-05-16 2012-02-29 Shionogi&Co., Ltd. Compounds Exhibiting PGD 2 Receptor Antagonism
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
TW200307542A (en) * 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) * 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) * 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
CN101454284A (zh) * 2006-05-26 2009-06-10 阿斯利康(瑞典)有限公司 联芳基或芳基-杂芳基取代的吲哚类化合物
MX2008015501A (es) 2006-06-08 2009-02-18 Neurokey As Uso de agonistas del receptor de canabinoide como farmacos inductores de hipotermia para el tratamiento de isquemia.
KR20090023645A (ko) 2006-06-28 2009-03-05 사노피-아벤티스 신규한 ｃｘｃｒ2 억제제

Also Published As

Publication number Publication date
TW200404778A (en) 2004-04-01
WO2004007451A1 (en) 2004-01-22
DE60330372D1 (de) 2010-01-14
ATE450506T1 (de) 2009-12-15
US20060111426A1 (en) 2006-05-25
ZA200500170B (en) 2006-02-22
CN1279023C (zh) 2006-10-11
BR0312729A (pt) 2005-05-10
SE0202241D0 (sv) 2002-07-17
DK1551802T3 (da) 2010-03-15
JP2010280680A (ja) 2010-12-16
JP2011116770A (ja) 2011-06-16
NO20050828L (no) 2005-04-05
NZ537606A (en) 2006-08-31
PT1551802E (pt) 2010-02-02
AU2003251260A1 (en) 2004-02-02
CA2492445A1 (en) 2004-01-22
JP2005537265A (ja) 2005-12-08
US7723373B2 (en) 2010-05-25
ES2335491T3 (es) 2010-03-29
MXPA05000646A (es) 2005-06-02
CN1678579A (zh) 2005-10-05
CY1109760T1 (el) 2014-09-10
AU2003251260B2 (en) 2007-04-26
JP4791729B2 (ja) 2011-10-12
EP1551802A1 (en) 2005-07-13
EP1551802B1 (en) 2009-12-02
SE0203713D0 (sv) 2002-12-13
US20100197756A1 (en) 2010-08-05
SI1551802T1 (sl) 2010-03-31
AR040498A1 (es) 2005-04-06

Similar Documents

Publication Publication Date Title
AP1850A (en) Spiroindolineplperidine derivatives
EG24050A (en) Heterocylocarboxamide derivatives
PL374718A1 (en) Azolidinone-vinyl fused-benzene derivatives
IL166121A0 (en) Indole-3-sulphur derivatives
EP1522540A4 (en) AZAARENE DERIVATIVES
PL376475A1 (en) N-substituted-2-oxodihydropyridine derivatives
AP2005003343A0 (en) Substituted pyrrolo-pyrazole derivatives as kinaseinhibitors
SI1594840T1 (sl) Derivati piperidin-benzensulfonamida
GB0317665D0 (en) Qinazoline derivatives
SI1682493T1 (sl) Amidoacetonitrilni derivati
PL1606277T3 (pl) Pochodne imidazol-4-iloetynylo-pirydyny
ZA200500471B (en) N-biarylmethyl aminocycloalkanecarboxamide derivatives
IL165572A0 (en) 1-Ä(indoÜ-3-yl)carbonylÜpiperazine derivatives
IL175189A0 (en) N-thiazol-2-yl-benzamide derivatives
PT1706373E (pt) Derivados de amidoacetonitrilo
AU2003222659A8 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
EP1531854A4 (en) O-DERIVATED NOCATHIACIN DERIVATIVES
GB0319793D0 (en) Pyridinylmorpholine derivatives
GB0213488D0 (en) 2-Naphthamide derivatives
AU2003243397A8 (en) Homo-camptothecin derivatives
GB0210512D0 (en) Tetrahydro-napthalene derivatives
GB0219894D0 (en) Dihydropyridinone derivatives
AU2003285777A8 (en) 3-substituted-4-pyrimidone derivatives
TWI341309B (en) Heteroarylcarbamoylbenzene derivatives
AU2003280822A8 (en) Beauveriolide derivatives